SCHEMBL14914337

SCHEMBL14914337

COc1cc(NC(=O)c2ccc(-c3ccccc3-c3ccc(F)c(F)c3F)c(CO)c2)ccc1S(N)(=O)=O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ HTT P42858 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ MAPT P10636 5/20 0.45
▸ POLB P06746 2/20 0.45
▸ STAT3 P40763 1/20 0.43
▸ PLAU P00749 1/20 0.42
▸ PLAT P00750 1/20 0.42
▸ LMNA P02545 3/20 0.42
▸ TP53 P04637 2/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ GAA P10253 1/20 0.41
▸ MCL1 Q07820 1/20 0.41
▸ NPC1 O15118 1/20 0.40
▸ NQO2 P16083 1/20 0.40
▸ CASP3 P42574 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ SENP7 Q9BQF6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14914046 0.97 MAPT (0.47) MEN1KMT2AALDH1A1HTTL3MBTL1
SCHEMBL14913925 0.93 MEN1 (0.43) MEN1KMT2AALDH1A1HTTL3MBTL1
SCHEMBL14914347 0.93 PLAU (0.47) MEN1KMT2AALDH1A1HTTL3MBTL1
SCHEMBL14914326 0.88 MAPT (0.42) MEN1KMT2AALDH1A1HTTL3MBTL1
SCHEMBL14914055 0.87 POLB (0.49) MEN1KMT2AMAPTPOLBSTAT3
SCHEMBL14914566 0.87 MCHR1 (0.49) MEN1KMT2AMAPTPOLBSTAT3
SCHEMBL14914056 0.86 STAT3 (0.52) MEN1KMT2AALDH1A1HTTMAPT
SCHEMBL14914479 0.85 MAPT (0.44) MEN1KMT2AALDH1A1HTTL3MBTL1
SCHEMBL14914788 0.85 MAPT (0.43) MEN1KMT2AALDH1A1HTTL3MBTL1
SCHEMBL10035104 0.84 MAPT (0.45) MAPTPOLBSTAT3LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2594554-A1 BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-05-22 — — EP claimed
US-20130116227-A1 BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-05-09 — — US claimed
EP-2594554-A1 BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-05-22 — — EP disclosed
US-20130116227-A1 BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116227-A1 BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF MC2R, NR3C2, REN MEN1 2885/4885KMT2A 1698/4885ALDH1A1 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback